Keros Therapeutics Inc

+0.03 (+0.08%)
Regulatory, Other Pre-Announcement

Keros Therapeutics Announces Results From Phase 2 Trial Evaluating Ker-050 In Patients With Myelodysplastic Syndromes

Published: 06/22/2021 20:11 GMT
Keros Therapeutics Inc (KROS) - Keros Therapeutics Announces Preliminary Results From Its Phase 2 Clinical Trial Evaluating Ker-050 in Patients With Myelodysplastic Syndromes.
Keros Therapeutics Inc - As of Data Cut-off Date, Ker-050 Was Well Tolerated in Cohorts 1 and 2 of Trial.
Keros Therapeutics Inc - No Drug-related Serious Adverse Events Were Reported in Trial.
Keros Therapeutics Inc - 2 Patients Withdrew From Trial Prior to Completing 8 Weeks of Treatment With Ker-050.
Keros Therapeutics Inc - Expects to Report Additional Part 1 Data and Initiate Part 2 of Trial by End of 2021.